State Street Corp Has $49.98 Million Stake in Spark Therapeutics, Inc. (ONCE)

State Street Corp cut its holdings in shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) by 5.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 836,580 shares of the biotechnology company’s stock after selling 46,146 shares during the period. State Street Corp owned 2.68% of Spark Therapeutics worth $49,984,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. American International Group Inc. grew its stake in shares of Spark Therapeutics by 17.4% in the first quarter. American International Group Inc. now owns 11,582 shares of the biotechnology company’s stock worth $618,000 after acquiring an additional 1,714 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock valued at $2,067,000 after purchasing an additional 122 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 650 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Spark Therapeutics by 5.2% during the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock valued at $97,487,000 after purchasing an additional 90,686 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Spark Therapeutics by 4.9% during the first quarter. Geode Capital Management LLC now owns 177,154 shares of the biotechnology company’s stock valued at $9,449,000 after purchasing an additional 8,284 shares in the last quarter. 77.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “State Street Corp Has $49.98 Million Stake in Spark Therapeutics, Inc. (ONCE)” was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://ledgergazette.com/2017/11/13/spark-therapeutics-inc-once-stake-decreased-by-state-street-corp.html.

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at $71.67 on Monday. Spark Therapeutics, Inc. has a 1 year low of $47.03 and a 1 year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million during the quarter, compared to analysts’ expectations of $1.40 million. During the same quarter in the prior year, the business posted ($1.07) earnings per share. The company’s revenue was up 45.8% compared to the same quarter last year. equities research analysts forecast that Spark Therapeutics, Inc. will post -7.62 EPS for the current year.

In other Spark Therapeutics news, CEO Jeffrey D. Marrazzo sold 21,350 shares of Spark Therapeutics stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $80.01, for a total transaction of $1,708,213.50. Following the completion of the sale, the chief executive officer now owns 251,350 shares of the company’s stock, valued at approximately $20,110,513.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $79.38, for a total value of $793,800.00. Following the completion of the transaction, the chief financial officer now directly owns 12,500 shares of the company’s stock, valued at approximately $992,250. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,080,850 shares of company stock worth $91,191,774. 7.30% of the stock is owned by company insiders.

A number of research analysts have weighed in on ONCE shares. Cantor Fitzgerald reissued a “buy” rating and issued a $105.00 target price (up previously from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a report on Friday, October 6th. Barclays PLC upped their price target on Spark Therapeutics from $104.00 to $107.00 and gave the stock an “overweight” rating in a research report on Friday, October 13th. Cowen and Company restated a “buy” rating and issued a $95.00 price target on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Finally, Chardan Capital restated a “buy” rating and issued a $100.00 price target on shares of Spark Therapeutics in a research report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $90.36.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply